Fluciclovine 18F

Drug Profile

Fluciclovine 18F

Alternative Names: 18F-Ge-148; 18F fluciclovine; [18F]-FACBC; Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic-acid; Anti-1-amino-3-F-18-fluorocyclobutane-1-carboxylic-acid; Anti-1-amino-3-fluorine-18-fluorocyclobutane-1-carboxylic acid; Anti-18-F-FACBC; Anti-18F-FABC; Anti-3-18F-FACBC; Anti-F-18-fluorocyclobutane-carboxylic-acid; Axumin; FACBC; Fluciclovine-F-18; GE-148; Ge-148-18F; Ge-148-F-18; NMK-36; Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emory University
  • Developer Blue Earth Diagnostics; Emory University; GE Healthcare; Memorial Sloan-Kettering Cancer Center; Nihon Medi-Physics
  • Class Amino acids; Carboxylic acids; Cyclobutanes; Imaging agents; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase III Glioma
  • Clinical Phase Unknown Breast cancer
  • No development reported Brain cancer; Head and neck cancer; Lung cancer; Parathyroid cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Brain-cancer(Diagnosis) in USA (IV, Injection)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Head-and-neck-cancer(Diagnosis) in USA (IV, Injection)
  • 10 Oct 2017 Blue Earth Diagnostics enters into a manufacturing and distribution agreement with Seibersdorf Laboratories for fluciclovine (18F) for Prostate cancer (Diagnosis)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top